Skip to content
zameds

Acetylcysteine (Gencetyl, Ukastyn, Rocylteine)

Acetylcysteine

Aurogen South Africa (Pty) Ltd

Registration

Applicant
Aurogen South Africa (Pty) Ltd
Registrations
6

Variants

ProductStrength and formRegistrationStatusScheduleLeaflets
Gencetyl 200 MG

EACH TABLET CONTAINS ACETYLCYSTEINE 200,0 mg

200 mg56013956/10.3/0139RegisteredNot determinedNone
Gencetyl 600 MG

EACH TABLET CONTAINS ACETYLCYSTEINE 600,0 mg

600 mg56014056/10.3/0140RegisteredNot determinedNone
Ukastyn 200 MG

EACH TABLET CONTAINS ACETYLCYSTEINE 200,0 mg

200 mg560141.13956/10.3/0141.139CancelledNot determinedNone
Ukastyn 600 MG

EACH TABLET CONTAINS ACETYLCYSTEINE 600,0 mg

600 mg560142.14056/10.3/0142.140CancelledNot determinedNone
Rocylteine 200 MG

EACH TABLET CONTAINS ACETYLCYSTEINE 200,0 mg

200 mg560143.13956/10.3/0143.139RegisteredNot determinedNone
Rocylteine 600 MG

EACH TABLET CONTAINS ACETYLCYSTEINE 600,0 mg

600 mg560144.14056/10.3/0144.140RegisteredNot determinedNone

Regulatory status

This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.

Listings for this ingredient that could not be applied to this product

  • S3: Acetylcysteine

    • when intended for injection or for the management of paracetamol overdosage;
    • except when used as a mucolytic in acute respiratory conditions for a maximum treatment period of 14 days. (S1)

    Consolidated Schedules 06 July 2026, lines 3109 to 3114

  • S1: Acetylcysteine

    • when used as a mucolytic in acute respiratory conditions for a maximum treatment period of 14 days;
    • except when intended for injection or for the management of paracetamol overdosage. (S3)

    Consolidated Schedules 06 July 2026, lines 102 to 106

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

C5H9NO3S163.20 g/mol

(2R)-2-Acetamido-3-sulfanylpropanoic acid

Drag to rotate. Structure from PubChem CID 12035.

SAHPRA documents

SAHPRA has not published a professional information or patient information leaflet for this product.

Background

Loading...
Loading Wikipedia summary

Research articles

Loading...
Loading PubMed articles